PGX-5FU StripAssay®
5-Fluorouracil Metabolism Pharmacogenomics
The PGX-5FU StripAssay® identifies patients unable to metabolize 5-fluorouracil at standard rates, preventing life-threatening toxic drug accumulation and enabling clinicians to adjust dosage or select alternative chemotherapeutic agents.
Key Features
5-FU Toxicity Risk Identification
Identifies patients who cannot metabolize 5-fluorouracil at standard rates, preventing life-threatening toxicity.
Dosage Optimization
Enables clinicians to adjust dosage or select alternative agents for patients at elevated 5-FU toxicity risk.
Broad Oncology Application
Relevant to multiple malignancies treated with 5-FU, including colorectal, breast, and head & neck cancers.
PCR & Reverse Hybridization
Based on reverse hybridization of biotinylated PCR products for accurate pharmacogenomic profiling.
For Research Use Only (RUO)
PGX-5FU StripAssay® is intended for research use only in the United States and is not FDA-cleared for diagnostic use.